— A NEW FORUM —
May 10–11, 2017

Stanford University, Palo Alto, California

View Photos & Highlights Video

THE LIGHT STORY


The LIGHT Forum: Leaders In Global Healthcare and Technology is a conference designed for leaders from a broad cross-section of executives and top policy makers in the health-care field to discuss the latest developments, challenges and opportunities shaping the industry. Working hand in hand with leading thinkers from Silicon Valley, the event provides attendees with an ideal forum for networking as well as rigorous analysis and foresight.

The global health-care industry is at a turning point. The rise of personalized medicine, fundamental change in how healthcare is paid for, an explosion of data, and the transformation of the industry into a “global game” are just some of the most powerful forces roiling the landscape. At the same time, dramatic advances in artificial intelligence mean that big data and so-called “deep learning” offer the potential of unprecedented insight and market power for those who figure out how to harness these tools.

The initiative has been conceived to help the world’s top healthcare executives seize the moment.

Three partners have created The LIGHT Forum. From the heart of Silicon Valley, Roam Analytics is pioneering the application of self-learning algorithms and the Roam Health Knowledge Graph to the ocean of public and private healthcare data, with the goal of delivering the right drugs to the right patients at an affordable price. Richard Attias & Associates is the world’s foremost creator and convener of high-level fora for engagement, discussion and action. WPP, a world leader in marketing communications, has years of experience working with many of the world’s largest healthcare companies.

Richard-Attias-Associates Roam WPP Health and Wellness

+

2017 EDITION SPEAKERS


Click on the speaker's photo to read his/her bio.

  • George Barrat

    George Barrett

    Chairman and Chief Executive Officer, Cardinal Health

    Adam Berger_website_112

    Adam Berger

    Chief Technology Officer, UPMC Enterprises

    Jay Bhattacharya

    Jay Bhattacharya, M.D.

    Professor of Medicine, Stanford University

  • Peter_Brabeck-High-resized-1

    Peter Brabeck-Letmathe

    Chairman Emeritus, Nestlé S.A.

    sp-Cheesbrough-Paul

    Paul Cheesbrough

    Chief Technology Officer, 21st Century Fox

    sp-Cohen-Ron

    Ron Cohen

    President, CEO and Founder, Acorda Therapeutics

  • sp-davis-gray

    Governor Gray Davis

    Former Governor of California; Of Counsel at Loeb & Loeb, LLP

    Hans-Georg Eichler

    Hans-Georg Eichler, M.D.

    Senior Medical Officer, European Medicines Agency

    Niall Ferguson

    Niall Ferguson

    Senior Fellow, Hoover Institution

  • Jeff George_11

    Jeff George

    Former Division Head & CEO, Sandoz and Alcon, Novartis Group

    sp-Glasspool-John

    John Glasspool

    Former Executive VP, Head of Corporate Strategy & Customer Operations at Baxalta

    gigijune_hirsh

    Gigi Hirsch, M.D.

    Executive Director, MIT Center for Biomedical Innovation

  • Mike Hudnall

    Mike Hudnall

    Global CEO, WPP Health & Wellness

    sp-Kindler-Jeff

    Jeffrey B. Kindler

    CEO
    of Centrexion Corporation

    Kumar-Shiva-1

    Shiva Kumar

    Vice President and Chief Strategy Officer, Watson Health at IBM

  • sp-Lonsdale-Joe

    Joe Lonsdale

    Partner, 8VC;
    Founder, Palantir and Addepar

    Andrew Maas_Website_1

    Andrew Maas

    Co-Chief Scientist, Roam Analytics

    Mark McClellan

    Mark McClellan, M.D.

    Director, Margolis Center for Health Policy at Duke University

  • Minor123

    Lloyd B. Minor, M.D.

    Dean, Stanford School of Medicine

    Mick Mulvaney_Website

    Mick Mulvaney

    Director, the Office of Management and Budget

    Peter-Portrait-June-16-small-format

    Peter Ohnemus

    Founder and CEO, Dacadoo

  • sp-Orszag-Peter

    Peter Orszag

    Vice Chairman of Investment Banking & Global Co-Head of Healthcare, Lazard Freres & Co. LLC

    Johnathon Peacock

    Jonathan Peacock

    Chairman, Arix Bioscience

    Potts-Chris

    Chris Potts

    Co-Chief Scientist, Roam Analytics

  • Robert Robbins

    Robert Robbins, M.D.

    President, University of Arizona

    sp-Robinson-Peter

    Peter M. Robinson

    Research Fellow, Hoover Institution

    Sahami-Mehran

    Mehran Sahami

    Professor, Stanford Artificial Intelligence Laboratory

  • sp-schaeffer-s

    Susan Schaeffer

    Editor, BioCentury

    judySewards

    Judy Sewards

    VP, Head of Digital Strategy; Data Innovation, Pfizer

    Andy Slavitt

    Andy Slavitt

    Former Acting Administrator, Centers for Medicare & Medicaid Services

  • Sir Martin Sorrell

    Sir Martin Sorrell

    Chief Executive, WPP

    John-Thornhill-photo

    John Thornhill

    Innovation Editor, The Financial Times

    Alex Turkeltaub_Web

    Alex Turkeltaub

    CEO and Co-Founder, Roam Analytics

George Barrat
George Barrett
Chairman and Chief Executive Officer, Cardinal Health

George Barrett is chairman and chief executive officer of Cardinal Health, a company ranked number 21 on the Fortune 500 and dedicated to improving the cost-effectiveness of health care.

Barrett has refocused Cardinal Health on its essential role in supporting hospitals, pharmacies and alternative sites of care in their efforts to improve the quality and safety of patient care, while reducing costs and improving efficiency. The tagline – Essential to care – embodies the company’s strategy and the culture of the organization.

Barrett has been chairman and CEO of Cardinal Health since 2009. He joined the company in 2008 as vice chairman and CEO of the company’s Healthcare Supply Chain Services.

From 2005 to end-2007, Barrett served as president and CEO of North America for Teva Pharmaceutical Industries. During 2007, he also served as corporate executive vice president for Global Pharmaceutical Markets. He held the position of president of Teva USA from 1999 to end-2004. Prior to joining Teva, Barrett held various positions with Alpharma Inc., serving as president of US Pharmaceuticals from 1994 to 1997, and president of NMC Laboratories, prior to its acquisition by Alpharma in 1990.

Barrett serves on the board of directors of the Federal Reserve Bank of Cleveland, Nationwide Children’s Hospital and the board of trustees of the Corporation of Brown University. He is a member of the Healthcare Leadership Council and The Conference Board. He is also a member of the Business Roundtable, The Business Council and The Columbus Partnership. Barrett also serves on the board of directors of the Rock and Roll Hall of Fame.

Barrett earned his Bachelor of Arts degree from Brown University and a Master of Business Administration from New York University. He also holds an Honorary Doctor of Humane Letters degree from Long Island University’s Arnold & Marie Schwartz College of Pharmacy and Health Sciences.

Adam Berger_website_112
Adam Berger
Chief Technology Officer, UPMC Enterprises

Adam Berger is the Chief Technology Officer of UPMC Enterprises, the innovation and commercialization arm of UPMC, a $14 billion integrated nonprofit health enterprise. Widely known for its leadership in technology, UPMC invests financial and intellectual capital into developing life-saving and cost-saving innovations for UPMC and the wider health care industry.

Adam received his PhD in computer science from Carnegie Mellon University, where he worked at the intersection of machine learning and language processing. Adam also worked at IBM TJ Watson Research, where he helped develop the maximum entropy technique for predictive modeling, and contributed to the groundbreaking “Candide” system for statistical machine translation. Adam has also founded two mobile software companies and led an R&D group at Nokia.

During his years in the software industry, Adam served as a technology advisor and board member to several startups and technology investment firms. He has published more than 20 refereed papers and holds over 20 U.S. patents.

Jay Bhattacharya
Jay Bhattacharya, M.D.
Professor of Medicine, Stanford University

Jay Bhattacharya’s research focuses on the constraints that vulnerable populations face in making decisions that affect their health status, as well as the effects of government policies and programs designed to benefit vulnerable populations. He has published over 100 peer-reviewed studies on the elderly, adolescents, obese patients, HIV patients, patients with kidney disease, patient with heart disease, and many other vulnerable populations, as well as a leading textbook on health economics. Dr. Bhattacharya is a research fellow at the National Bureau of Economics Research and a senior fellow at the Stanford Institute for Economic Policy Research. He holds an MD and a PhD in economics, both from Stanford University.

Peter_Brabeck-High-resized-1
Peter Brabeck-Letmathe
Chairman Emeritus, Nestlé S.A.
sp-Cheesbrough-Paul
Paul Cheesbrough
Chief Technology Officer, 21st Century Fox

Paul Cheesbrough is Chief Technology Officer for 21st Century Fox. In this role Mr. Cheesbrough oversees the company’s technology strategy and operations on a global basis. He joined 21st Century Fox in December 2016.

Prior to this, he served as Chief Technology Officer for News Corp, overseeing the enterprise technologies and digital products and platforms across the business as well as the technology investment portfolio. In this role he led significant change across the business, moving it to more cloud-based technologies and putting innovation and engineering at the heart of the organizations owned by the company.

Before joining News Corp, Mr. Cheesbrough served as Chief Information Officer at the Telegraph Media Group, where he pioneered the development of a wide range of new digital products. Prior to the Telegraph, he was the Controller of Digital Media for the BBC, having started his career in IBM within its media division as a software engineer.

sp-Cohen-Ron
Ron Cohen
President, CEO and Founder, Acorda Therapeutics

Ron Cohen, M.D. is President, CEO and founder of Acorda Therapeutics, Inc., a public biotechnology company developing therapies for disorders of the nervous system, including multiple sclerosis, Parkinson’s disease, stroke and epilepsy. Dr. Cohen previously was a principal in the startup and an officer of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ tissues for transplantation uses. He is Chair of the Board of the Biotechnology Industry Organization (BIO), and serves on the Board of Directors of VBL Therapeutics. Dr. Cohen previously served as Chair of the Emerging Companies Section of the BIO Board and is a former Director and Chair of the New York Biotechnology Association (NYBA). He also serves as a member the Columbia-Presbyterian Health Sciences Advisory Council and was awarded Columbia University’s Alumni Medal for Distinguished Service.

Acorda Therapeutics has been recognized as one of the Best Companies to Work for in New York State 7 years in a row (2011-2017) and among the Fortune 100 Best Workplaces for Women in the U.S.

Dr. Cohen is a recipient of the NY CEO Lifetime Achievement Award and the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region. He was named Neuroinvestment’s CEO of the Year and is an inductee of the National Spinal Cord Injury Association’s “Spinal Cord Injury Hall of Fame.” Dr. Cohen received the Burke Award from Burke Rehabilitation Hospital for his contributions to helping people with disabilities gain independence. He has been recognized by the New York Biotechnology Association as the NYBA “The Cures Start Here” Business Leader of the Year, by the Westchester County Association as its Leadership Award recipient, and by PharmaVOICE Magazine as one of the 100 Most Inspirational People in the Biopharmaceutical Industry.

Dr. Cohen received his B.A. degree with honors in Psychology from Princeton University, and his M.D. from the Columbia College of Physicians & Surgeons. He completed a residency in Internal Medicine at the University of Virginia Medical Center, and is Board Certified in Internal Medicine.

sp-davis-gray
Governor Gray Davis
Former Governor of California; Of Counsel at Loeb & Loeb, LLP

Joseph "Gray" Davis was elected the 37th governor of California in 1998, winning 58 percent of the vote.

As Governor, he made education a top priority, signing legislation to strengthen California's K-12 system by establishing the Academic Performance Index to increase accountability in schools, and expanding access to higher education with a record number of scholarships and college loans. These reforms improved student achievement scores for six consecutive years. While presiding over California during an unprecedented economic expansion – where the State became the 5th largest global economy, Davis made record investments in infrastructure, created four Centers of Science and Innovation on UC campuses, and expanded state health insurance for an additional one million children. He also was the first Governor in the nation to authorize stem cell research.

As Governor he demonstrated bold environmental leadership by signing the first law in the nation to reduce global warming and greenhouse gases. He also created the first Greenhouse Gas Monitoring Registry, and was the first to establish the nation's most ambitious commitment to renewable energy by creating the statewide Renewables Portfolio Standard.

Despite a wave of Republican victories across the nation in 2002, Davis was re-elected to a second term.

Davis graduated from Stanford University (Cum Laude) and Columbia Law School, and was awarded the Bronze Star for his service during the Vietnam War. He served as lieutenant governor (1995-1998), state controller (1987-95), and state assemblyman (1982-86).

Davis is Of Counsel in the Los Angeles office of Loeb & Loeb, LLP where he provides strategic advice to clients on numerous matters. He is also a member of the bi-partisan Think Long Committee, a Senior Fellow at the UCLA School of Public Affairs, Co-Chair of the Southern California Leadership Council, and speaks before a number of civic and government organizations on important issues of the day. Governor Davis was also honored to be the Keynote Speaker at the Columbia Law School Graduation Ceremony in May of 2009.

Hans-Georg Eichler
Hans-Georg Eichler, M.D.
Senior Medical Officer, European Medicines Agency

Hans-Georg Eichler, M.D., M.Sc., is the Senior Medical Officer at the European Medicines Agency in London, United Kingdom, where he is responsible for coordinating activities between the Agency’s scientific committees and giving advice on scientific and public health issues.

Prior to joining the European Medicines Agency, Dr. Eichler was at the Medical University of Vienna in Austria for 15 years. He was vice-rector for Research and International Relations since 2003, and professor and chair of the Department of Clinical Pharmacology since 1992. His other previous positions include president of the Vienna School of Clinical Research and co-chair of the Committee on Reimbursement of Drugs of the Austrian Social Security Association. His industry experience includes time spent at Ciba-Geigy Research Labs, U.K., and Outcomes Research at Merck & Co., in New Jersey.

Dr. Eichler graduated with an M.D. from Vienna University Medical School and a Master of Science degree in Toxicology from the University of Surrey in Guildford, U.K. He trained in internal medicine and clinical pharmacology at the Vienna University Hospital as well as at Stanford University.

Niall Ferguson
Niall Ferguson
Senior Fellow, Hoover Institution

Niall Ferguson is a senior fellow of the Hoover Institution, Stanford, and a senior fellow of the Center for European Studies, Harvard. He is also a visiting professor at Tsinghua University, Beijing, and the Diller-von Furstenberg Family Foundation Distinguished Scholar at the Nitze School of Advanced International Studies in Washington, DC.

He has written fourteen books, including The House of Rothschild, Empire, The War of the World, The Ascent of Money, The Great Degeneration, and Kissinger, 1923-1968: The Idealist, which won the 2016 Council on Foreign Relations Arthur Ross Book Award.

His 2011 feature-length film Kissinger won the New York International Film Festival’s prize for best documentary. His PBS series The Ascent of Money won the International Emmy for best documentary. His many prizes and awards include the Benjamin Franklin Prize for Public Service (2010), the Hayek Prize for Lifetime Achievement (2012), the Ludwig Erhard Prize for Economic Journalism (2013), and the Philip Merrill Award of the American Council of Trustees and Alumni for Outstanding Contributions to Liberal Arts Education (2016).

He writes a weekly column for the London Sunday Times and the Boston Globe.

Jeff George_11
Jeff George
Former Division Head & CEO, Sandoz and Alcon, Novartis Group

Jeff served on the Novartis Group Executive Committee from 2008 to 2016, first as Division Head and CEO of Sandoz (2008-2014), Novartis’s $10 billion generic pharmaceuticals and biosimilars subsidiary, and then as Division Head and CEO of Alcon (2014-2016), Novartis’s $10 billion eye care subsidiary. Prior to this, he was Head of Emerging Markets at Novartis Pharmaceuticals for the Middle East, Africa, Southeast Asia and CIS, after serving as Vice President and Head of Western & Eastern Europe for Novartis Vaccines.

In both of his divisional CEO roles, Jeff was responsible for leading over 25,000 associates globally across more than 160 countries and had primary line leadership and management responsibility for all functions, regions, and franchises. Sandoz is the second-largest generic pharmaceuticals company globally. Sandoz sales grew by over $1.7 billion during his tenure to $9.2 billion in 2013, despite a significant foreign exchange impact. Sandoz also became the global leader in biosimilars during this time, while attaining #1 positions globally in differentiated generic segments including dermatologics, ophthalmics, and injectables. Alcon was the largest ophthalmology company globally in 2016, operating across the ophthalmic pharmaceuticals, surgical and vision care segments. Acquired for $52 billion in 2011, Alcon was restructured in 2016, with the $4 billion pharma business moving into Novartis Pharma.

Before joining Novartis, Jeff was Senior Director of Strategic Planning and Business Development at Gap Inc., where he led growth, licensing, and European expansion efforts for one of its apparel divisions. Prior to this he was an Engagement Manager at McKinsey & Company in San Francisco. Jeff has also worked in emerging markets private equity in South Africa and in Washington, D.C.

Jeff holds an MBA from Harvard Business School and a master’s degree from Johns Hopkins University’s School of Advanced International Studies (SAIS), where he studied international economics and emerging markets political economy and was awarded the John W. Watzek Fellowship. He received his B.A. in international relations, magna cum laude and Phi Beta Kappa, from Carleton College. Jeff served on the Board of Directors for AdvaMed, the medical device industry association, from 2014 to 2016, and is a member of the Young President’s Organization (YPO). He was twice named to Fortune’s “40 under 40” list of up-and-coming leaders. He has lived in seven countries on four continents and is married with two daughters. He enjoys running, soccer, live music, meditation, and traveling with family and friends.

sp-Glasspool-John
John Glasspool
Former Executive VP, Head of Corporate Strategy & Customer Operations at Baxalta

As a seasoned pharmaceutical executive with over 25 years of experience in the industry, Royston John Glasspool has extensive experience in multiple line and staff functions in the US, UK, Europe, and global markets through his roles of increasing responsibility at Scotia Pharmaceuticals, Johnson & Johnson, Novartis, Baxter, and Baxalta. This experience has helped him architect innovative approaches to patient-centered drug development within the companies he has served, such as the P5 planning process and patient access approach. He has led franchises with over $6B in sales and has launched over 10 products. He is regularly invited to expert panels and also serves on the Board of Directors of the Biotechnology Industry Organization (BIO). John holds 2 patents and has degrees in politics and international relations from the University of Staffordshire, UK, and in business administration from Oxford Brookes University with a focus on international marketing. Before joining the pharmaceutical industry, John owned a restaurant and small hotel.

John lives in Hingham, MA with his wife Susan, daughter Samantha, and cat Sushi.

gigijune_hirsh
Gigi Hirsch, M.D.
Executive Director, MIT Center for Biomedical Innovation

Dr. Hirsch is the Executive Director of the MIT Center for Biomedical Innovation (CBI), which focuses on improving global health by overcoming challenges to the development, diffusion and adoption of biomedical innovations.

Her current efforts at CBI center on leading the New Drug Development Paradigms initiative (NEWDIGS), a “think and do tank” that is re-engineering pharmaceutical innovation to reliably and sustainably deliver new, better, affordable therapeutics to the right patients, faster. Utilizing the broad strategic framework of “Adaptive Biomedical Innovation (ABI),” NEWDIGS’ flagship project focuses on aligning stakeholders around more adaptive, patient-centered approaches to the management of risk and uncertainty across the life span of new medicines. This project helped inspire the Adaptive Pathways pilot program launched by the European Medicines Agency (EMA) in March 2014.

Under Dr. Hirsch’s leadership, NEWDIGS continues to channel multi-stakeholder thought leadership to advance other critical enablers of ABI such as adaptive financing and reimbursement of curative therapies in the US; real world evidence standards; and interactive simulation methods/tools for collaborative innovation.

Dr. Hirsch has held a number of leadership roles that leverage her broad clinical background (Internal Medicine, Emergency Medicine, and Psychiatry) along with her passion for addressing the innovation gap between science and the system. While at MIT she served on the President’s Council of Advisors on Science & Technology (PCAST) in the US. Prior to joining MIT, she worked in commercial strategy at Millennium Pharmaceuticals, and was founder and CEO of a boutique entrepreneurial venture, funded by Boston’s Beth Israel Hospital. She has held faculty appointments at the medical schools of Harvard, Brown, and Tufts.

Mike Hudnall
Mike Hudnall
Global CEO, WPP Health & Wellness

As global CEO of WPP Health & Wellness, Mike guides the company’s strategic vision, focused on helping clients accelerate value, and better health outcomes.

Mike’s passion for health, technology, and intelligent innovation in marketing have been driving a force throughout his career. As an early digital entrepreneur, he founded, led, and sold agencies that pioneered cutting edge technologies for some of the world’s leading healthcare businesses. When Mike joined WPP as a Global Client Leader in 2012, he built and led one of WPP’s largest client engagements, setting new standards for partnership and leveraging the power of WPP’s vast network to accelerate business transformation. Recognized as a tenacious, results oriented leader, Mike was appointed to lead WPP Health & Wellness – the network’s first operating company to bear the WPP name – in 2016.

In line with his commitment to health and wellness, Mike is an avid runner, a P3 Krav Maga practitioner, and an active father of two. He holds a B.S. in Marketing from Villanova University.

sp-Kindler-Jeff
Jeffrey B. Kindler
CEO
of Centrexion Corporation

Jeff Kindler is a healthcare executive, investor and advisor who has held leadership positions at some of the world's most recognized companies. With more than three decades of experience, Kindler is a leading expert in pharmaceuticals and other health care sectors; corporate legal matters including regulation, litigation, compliance and crisis management; brand and franchise management; board and corporate governance; and executive leadership.

Currently, Kindler serves as CEO of Centrexion Corporation, a privately held biotherapeutics company developing pain therapies; Executive Chairman of vTv, a pharmaceutical development company; Venture Partner at Lux Capital, a leading venture capital firm; Managing Director at Starboard Capital Partners, a private equity firm; and a principal in and advisor to a number of privately held health care firms and sponsors. He is also Global Chair of the GLG Institute, a membership-based learning community for leading executives, and serves as a member of President Obama's Management Advisory Board.

Kindler serves on the boards of a number of publicly and privately held health care companies as well as several not-for-profit institutions including Tufts University.

Kindler was formerly the Chairman and Chief Executive Officer of Pfizer, the world's largest research-based biopharmaceutical company, which he joined in January 2002. As CEO, Kindler led Pfizer’s $68 billion merger and acquisition of Wyeth, diversified Pfizer’s product portfolio, improved its R&D pipeline, and reshaped the company’s commercial, innovation, and leadership models to drive growth and cultural change. He joined Pfizer as Executive Vice President and General Counsel and, prior to his appointment as CEO in July 2006, he served as a Vice Chairman of the company, responsible for Pfizer’s corporate affairs including worldwide legal, regulatory and patent matters as well as a range of public affairs and communications functions, and serving as a member of the four-person executive committee overseeing global business operations.

While at Pfizer, Kindler worked with former President Bill Clinton to help bring medicines to impoverished patients in the developing world through public-private pharmaceutical partnerships. He also represented the pharmaceutical industry in U.S. government healthcare reform efforts, helping to increase access to affordable medicines while preserving an environment in which pharmaceutical firms can discover and develop innovative treatments.

In 1996, Kindler joined McDonald's Corporation as Executive Vice President and General Counsel, responsible for both legal and corporate affairs, and then moved into line management as President of Partner Brands, which included overseeing franchise, operations and marketing efforts for restaurant brands such as Boston Market, Chipotle Mexican Grill, Donato’s Pizza, and Pret a Manger. Before joining McDonald’s Corporation, Kindler was Vice President of Litigation and Legal Policy of the General Electric Company.

Prior to GE, Kindler practiced civil and criminal litigation as a partner at the Washington D.C. firm of Williams & Connolly. He began his career as an attorney at the Federal Communications Commission and served as a law clerk to Judge David L. Bazelon of the U.S. Court of Appeals of the D.C. Circuit and later as law clerk to U.S. Supreme Court Justice William J. Brennan, Jr.

Kindler earned his BA in 1977 from Tufts University summa cum laude and his JD in 1980 from Harvard magna cum laude, where he was an editor of the Harvard Law Review.

Kumar-Shiva-1
Shiva Kumar
Vice President and Chief Strategy Officer, Watson Health at IBM

Shiva Kumar is currently the Vice President and Chief Strategy officer of IBM’s Watson Health division. For the past several years he has provided the impetus for IBM to build a “Cognitive” business in Health and Life Sciences. He cares deeply about improving and saving lives of people around the world.

Shiva has a deep understanding of digital disruption and value migration caused by technology adoption across several industries and domains. He has helped create the “new” IBM by enabling new business models and new businesses. He led teams in IBM Research to create capabilities at the convergence of information flow, work flow, Big Data and Analytics. These capabilities created the underpinnings of some of the new businesses IBM has launched.

For many years, Shiva led teams in IBM’s Enterprise Transformation organization to improve business performance across IBM’s execution units. The teams applied analytics and insights to enable growth of revenues and labor effectiveness. Many of the innovations have enabled new ways in which IBM runs its businesses.

Before joining IBM, Shiva was an Associate Principal in McKinsey & Company’s Stamford Office, where he worked in the areas of business building related to technology and the use of Analytics to improve business performance. He served clients in many industries as a member of McKinsey’s High Tech and Business Building practices.

Mr. Kumar received an M.Sc. degree from the Indian Institute of Technology, Kanpur, India, and a Ph. D. from Yale University, both in Physics. Subsequently, he worked as an Associate Professor of Physics at Yale University.

sp-Lonsdale-Joe
Joe Lonsdale
Partner, 8VC;
Founder, Palantir and Addepar

Joe Lonsdale is a founding partner at 8VC, a San Francisco-based venture capital fund. He serves on several boards including Addepar, OpenGov, Oscar, Illumio, Radius, Hyperloop-One and Wish.

Joe is a co-founder of Palantir, a multi-billion dollar global software company best known for its work in defense and finance. Most recently, he was a founding partner at Formation 8, the precursor fund to 8VC, which manages over 1.5 billion USD and is one of the top performing private funds. Before that, he founded Addepar, a leading wealth management technology platform, and OpenGov. Previously, Joe was an early executive at Peter Thiel's Clarium Capital, which they grew into a large global macro hedge fund. He also worked with the financial arm of PayPal while he was at Stanford.

Joe received a B.S. in Computer Science from Stanford in 2003. He often lectures and writes on entrepreneurship and technology.

Andrew Maas_Website_1
Andrew Maas
Co-Chief Scientist, Roam Analytics

Andrew graduated with a PhD in Computer Science from Stanford University in 2015, advised by Andrew Ng and Dan Jurafsky. His research focuses on large scale deep learning to solve some of the most challenging problems in data analytics and forecasting, speech recognition, natural language processing, and computer vision. Andrew has consulted for Coursera, where he built biometric classifiers; for other clients he has developed recommendation systems for TV content and unsupervised similarity discovery algorithms for legal patents. Andrew received his B.S. from Carnegie Mellon in 2009. In 2017, he was voted by Forbes as a top 30 UNDER 30 in Enterprise Technology.

Mark McClellan
Mark McClellan, M.D.
Director, Margolis Center for Health Policy at Duke University

Mark McClellan, MD, PhD, is the Robert J. Margolis Professor of Business, Medicine, and Policy, and Director of the Margolis Center for Health Policy at Duke University. He is a physician- economist who focuses on quality and value in health care including payment reform, real-world evidence and more effective drug and device innovation. He is former administrator of the Centers for Medicare & Medicaid Services and former commissioner of the U.S. Food and Drug Administration, where he developed and implemented major reforms in health policy. He was previously Senior Fellow at the Brookings Institution and a faculty member at Stanford University.

Minor123
Lloyd B. Minor, M.D.
Dean, Stanford School of Medicine

Lloyd B. Minor, MD, is the Carl and Elizabeth Naumann Dean of the Stanford University School of Medicine. With his leadership, Stanford Medicine has established a strategic vision to lead the biomedical revolution in Precision Health with a focus on proactive, preventive, predictive, and personalized heath care. Dr. Minor is also a professor of Otolaryngology–Head and Neck Surgery and a professor of Bioengineering and of Neurobiology, by courtesy, at Stanford University. With more than 140 published articles and chapters, Dr. Minor is an expert in balance and inner ear disorders. In 2012, he was elected to the National Academy of Medicine.

Mick Mulvaney_Website
Mick Mulvaney
Director, the Office of Management and Budget

Mick Mulvaney is the current director of the Office of Management and Budget (OMB). He was nominated to the post by President Donald J. Trump in December 2016 and confirmed by the Senate on February 16, 2017.

Prior to his time as the director of OMB, he served the people of the 5th District of South Carolina as their Congressman where he was first elected in 2010, he is the first Republican member to hold the seat in 128 years.

A lifelong Carolinas resident, he attended Georgetown University, graduating with honors in International Economics, Commerce, and Finance and graduated as an Honor Scholar – the highest award given to students of the Georgetown School of Foreign Service.

After college, Mick received his law degree from the University of North Carolina at Chapel Hill on a full academic scholarship. He completed his formal education at Harvard Business School's OPM program in 2006.

In addition to practicing law and opening his own firm, he also ran the family real estate business, started a small homebuilding company, and became a minority shareholder in a local family restaurant franchise.

While in Congress, he served on the Budget Committee, Joint Economic Committee, Small Business Committee, Financial Services Committee, and the Oversight and Government Reform Committee.

He was a founding member of the Indian Land Rotary, a member of St. Philip Neri Catholic Church, and founding member of Our Lady of Grace Catholic Mission.

Mick and Pam were married in 1998, and are the proud parents of triplets: James, Caroline, and Finnegan, and two great danes: Guiness and Harper.

Peter-Portrait-June-16-small-format
Peter Ohnemus
Founder and CEO, Dacadoo

Peter Ohnemus is the founder of the dacadoo Health Score/dacadoo ag, Zurich/Switzerland. The patented dacadoo Health Score & Lifestyle Navigation Platform is being licensed to key Life & Health Insurance companies and global healthcare operators. Peter has been involved in high-tech and bio-tech investments over the last 25 years and this had led to four IPO’s and multiple trade sells.

Peter was CEO & co-founded ASSET4 in 2004 with Goldman Sachs and Merrill Lynch as investors (the world’s leading provider of extra-financial information), which was sold to Thomson Reuters, New York in November 2009. Peter Ohnemus previously held senior executive positions with Sybase, Logic Works, The Fantastic Corporation and COS – all of which went public during his tenure. Peter Ohnemus was Entrepreneur of the Year (EoY) for Switzerland by EY.

Peter is a frequent speaker and commenter on high-tech and healthcare globally. He has spoken at World Economic Forum (WEF), Fortune Brainstorm Health, Google Tech Talks, McKinsey’s Life Leaders CEO Forum, CommunicAsia, Mobile World, European Health Forum by the EU, Economist Global Healthcare Forum, Mobile Health Summit DC, European Tech Tour, Red Herring, WWW/Digital Disease Detection, etc. Over the last 10 years Peter has been board member of Rothschild Bank, Tele Denmark (Switzerland), Esbatech, CommerceOne, etc. Peter occasionally teaches digital innovation, entrepreneurship and economic impact at Universities such as HSG - Switzerland, Bocconi - India. Peter lives outside Zürich, is married and has 5 daughters.

sp-Orszag-Peter
Peter Orszag
Vice Chairman of Investment Banking & Global Co-Head of Healthcare, Lazard Freres & Co. LLC

Prior to joining Lazard, Mr. Orszag was with Citigroup (since 2011), where he was Vice Chairman of Corporate and Investment Banking at Citigroup, and Chairman of Citi’s Financial Strategy and Solutions Group.  He is also a nonresident Senior Fellow in Economic Studies at the Brookings Institution.

Mr. Orszag previously served as a Distinguished Visiting Fellow at the Council on Foreign Relations (2010-2015).  He was the Director of the Office of Management and Budget (2009-2010), serving in President Barack Obama’s cabinet, and Director of the Congressional Budget Office (CBO) (2007-2008).

Before leading the CBO, Mr. Orszag served as Director of The Hamilton Project (generating innovative solutions to support broad-based economic growth) and the Retirement Security Project (promoting retirement security amongst moderate- and lower-income families).

Johnathon Peacock
Jonathan Peacock
Chairman, Arix Bioscience

Jonathan Peacock was the former CFO of Amgen Inc. based in California and prior to that CFO of the Pharmaceuticals Division of Novartis AG, based in Switzerland. Before joining the pharma industry, Jon was a partner at McKinsey and Co, where he was co-head of the European Corporate Finance practice, and was also a partner at Price Waterhouse in London and New York from 1993-98. He is a graduate of the University of St Andrews in Scotland.

Jon is currently Chairman of Arix Bioscience, a biotech investment company based in London and New York, Chairman of Bellerophon Therapeutics, with late stage development programs addressing the treatment of pulmonary hypertension, a Board member of Kite Pharma, a company in the forefront of cancer therapies that harness the immune system and a Board member of Avantor, a leading supplier to the manufacturing divisions of companies in the BioPharma industry.

Potts-Chris
Chris Potts
Co-Chief Scientist, Roam Analytics
Chris Potts is Professor of Linguistics and, by courtesy, of Computer Science at Stanford, and Director of the Center for the Study of Language and Information (CSLI) at Stanford. In his research, he develops computational models of linguistic reasoning, emotional expression, and dialogue. He is the author of the 2005 book The Logic of Conventional Implicatures as well as numerous scholarly papers in linguistics and natural language processing.
Robert Robbins
Robert Robbins, M.D.
President, University of Arizona
sp-Robinson-Peter
Peter M. Robinson
Research Fellow, Hoover Institution

Peter M. Robinson is a research fellow at the Hoover Institution, where he writes about business and politics, edits Hoover's quarterly journal, the Hoover Digest, and hosts Hoover's video series program, Uncommon Knowledge™.

Robinson is also the author of three books: How Ronald Reagan Changed My Life (Regan Books, 2003); It's My Party: A Republican's Messy Love Affair with the GOP, (Warner Books, 2000); and the best-selling business book Snapshots from Hell: The Making of an MBA (Warner Books, 1994; still available in paperback).

In 1979, he graduated summa cum laude from Dartmouth College, where he majored in English. He went on to study politics, philosophy, and economics at Oxford University, from which he graduated in 1982.

Robinson spent six years in the White House, serving from 1982 to 1983 as chief speechwriter to Vice President George Bush and from 1983 to 1988 as special assistant and speechwriter to President Ronald Reagan. He wrote the historic Berlin Wall address in which President Reagan called on General Secretary Mikhail Gorbachev to "tear down this wall!"

After the White House, Robinson attended the Stanford University Graduate School of Business. (The journal he kept formed the basis for Snapshots from Hell.) He graduated with an MBA in 1990.

Robinson then spent a year in New York City with Fox Television, reporting to the owner of the company, Rupert Murdoch. He spent a second year in Washington, D.C., with the Securities and Exchange Commission, where he served as the director of the Office of Public Affairs, Policy Evaluation, and Research. Robinson joined the Hoover Institution in 1993.

The author of numerous essays and interviews, Robinson has published in the New York Times, Red Herring, and Forbes ASAP, the Wall Street Journal, and National Review Online. He is the editor of Can Congress Be Fixed?: Five Essays on Congressional Reform (Hoover Institution Press, 1995).

In 2005, Robinson was elected to serve as a Trustee of Dartmouth College.

Robinson lives in northern California with his wife, their children and their dog, Crusoe.

Sahami-Mehran
Mehran Sahami
Professor, Stanford Artificial Intelligence Laboratory

Mehran Sahami is a Professor and Associate Chair for Education in the Computer Science department at Stanford University.

He is also the Robert and Ruth Halperin University Fellow in Undergraduate Education. Prior to joining the Stanford faculty in 2007, he was a Senior Research Scientist at Google for several years. His research interests include computer science education, machine learning, and web search.

He has published numerous papers and has over 20 patent filings on a variety of topics including machine learning, data analytics, web search, recommendation engines in social networks, and email spam filtering that have been deployed in commercial applications.

sp-schaeffer-s
Susan Schaeffer
Editor, BioCentury

Susan serves as Editor of BioCentury. She has been reporting and commenting on the biopharmaceutical industry for 13 years, covering drug discovery and development, corporate strategy and finance, and regulation and policy as it affects multiple stakeholders in the biomedical ecosystem. Her work has been cited in regulatory filings and has recently influenced biopharma executives to lobby for legislative changes necessary to enable greater experimentation with pricing models designed to make innovation more affordable to healthcare systems.

She was previously Senior Editor in charge of Product Discovery & Development coverage from 2010 through 2012. She was Managing Editor of BioCentury and BioCentury Extra from 2004 through 2010. She joined BioCentury in 2003 after 10 years as an editor in the consumer packaged goods sector, including work with international strategy consultants Kurt Salmon Associates.

judySewards
Judy Sewards
VP, Head of Digital Strategy; Data Innovation, Pfizer

Judy Sewards serves as VP, Head of Digital Strategy & Data Innovation at Pfizer, where she is responsible for accelerating the adoption of robust digital and data solutions and compliant policies across the enterprise. In this role, she leads a team focused on bringing to market those future strategies that will have the greatest impact in engaging customers and meeting business needs in a rapidly changing health landscape.

In her tenure at Pfizer, Judy has held various leadership positions across the organization including Team Leader for the US Celebrex and Flector Patch businesses, Head of the Primary Care US Marketing Innovation Incubator and Consumer Lead for the iconic Viagra brand. Prior to Pfizer, Judy led client insights, brand strategy and advertising for the Merrill Lynch Global Wealth Management brand. In addition, she brings diverse experience ranging from tech start up to brand planning and management consulting.

Judy received her BA degree from Smith College, where she also served as a member of the Board of Trustees.

Andy Slavitt
Andy Slavitt
Former Acting Administrator, Centers for Medicare & Medicaid Services

Andy Slavitt has decades of private and public sector leadership in health care. Over his career, Andy has shaped some of the most significant and successful initiatives in health care impacting millions of Americans and the shape of the health care system. For 2015 to 2017, he served as the Acting Administrator for the Centers for Medicare & Medicaid Services (CMS) under Presi- dent Obama, overseeing the Medicaid, Medicare, the Children’s Health Insurance Program, and the Health Insurance Marketplace, where he also oversaw the healthcare.gov turnaround in 2013. Under his leadership, the U.S. health care system saw record reductions in the uninsured rate, nationwide improvements in quality, record low cost growth, and a major resurgence in value-based payment models.

From 2003 to 2013, Andy worked at UnitedHealth Group, eventually serving as the Group Ex- ecutive Vice President for Optum. Andy founded and served as CEO of HealthAllies, a technol- ogy-based consumer health care company, was also a consultant with McKinsey & Company, and an investment banker with Goldman Sachs. Andy recently joined the Bipartisan Policy Cen- t er in Washington, DC as a senior advisor.

In 2016 Andy was named one of the 10 most influential people in health care by Modern Health- care magazine, and he recently received the American Medical Association’s Dr. Nathan Davis Award for Outstanding Government Service. Andy is on USA Today’s board of contributors, writ- ing regular opinion pieces. He has also been published by The Washington Post, Politico and U S News, and is a frequent pundit on health care issues on MSNBC, Fox and other networks.

Andy lives in Minnesota with his family. He is a graduate of the Wharton School and The Col- lege of Arts & Sciences at the University of Pennsylvania, and received an MBA from Harvard Business School.

Sir Martin Sorrell
Sir Martin Sorrell
Chief Executive, WPP

Sir Martin Sorrell founded WPP, the world’s largest advertising and marketing services group in 1985 and has been chief executive throughout.

WPP companies, which include some of the most eminent agencies in the business, provide clients with advertising, media investment management, data investment management, public relations and public affairs, branding and identity, healthcare communications, direct, digital, promotion and relationship marketing and specialist communications services.

Collectively, WPP employs over 205,000 people (including associates and investments) in over 3,000 offices in 112 countries. The Group’s worldwide companies include J Walter Thompson, Ogilvy & Mather, Y&R, Grey, Mindshare, MEC, MediaCom, Kantar, Wunderman, Burson-Marsteller, Hill+Knowlton Strategies, Landor, Brand Union, Fitch, The Partners, AKQA, WPP Digital and WPP Health & Wellness. Clients include 360 of the Fortune Global 500, all 30 of the Dow Jones 30 and 78 of the NASDAQ 100. In 2016, WPP had revenues of over $19 billion and billings of $74 billion.

Sir Martin actively supports the advancement of international business schools – advising Harvard, IESE, the Indian School of Business, the China Europe International Business School and Fundação Dom Cabral Business School in Brazil. He has been publicly recognised with a number of awards including the Harvard Business School Alumni Achievement Award. In the Time 100 “Builders & Titans” he was voted one of the world’s most influential figures in business. He was also nominated for CNBC’s First 25 List (“Rebels, Icons and Leaders”) of people judged to have had the most profound impact on business and finance in the last 25 years. He received a knighthood in January 2000. He was awarded the 2014 Hugo Shong Lifetime Achievement Award in Communication by Boston University’s College of Communications. In October 2016, Sir Martin was ranked Britain’s best-performing CEO and was named the second best-performing CEO in the world by Harvard Business Review.

Sir Martin contributes to many important organisations and charities. He is on the Executive Committee of the World Economic Forum International Business Council (having been chairman from 2010-2012) and a member of the Business Council in the US. He is a member of the corporate Advisory Group of the Tate Gallery and on the International Advisory Board of The Russian Museum in St. Petersburg. In 2010 he was appointed to the Board of Directors of the Bloomberg Family Foundation. He is a member of the Advisory Board of Stanhope Capital and Bowmark Capital Group.

He is chairman of IBAC London, IBAC Rome and IBAC Jerusalem.

John-Thornhill-photo
John Thornhill
Innovation Editor, The Financial Times

John was appointed the Innovation Editor on February 2016. Prior to that John has been the deputy editor at the Financial Times since September 2012. He was appointed Financial Times’ news editor, based in London on the main news desk, in January 2009. Prior to this he spent four years in Paris as the editor of the European edition of the Financial Times.

Joining the FT in 1988 as a graduate trainee, Thornhill has been the Paris bureau chief, world news editor, Asia editor, Moscow bureau chief and a Lex columnist.

John founded and runs the FT's 125 executive forum, which holds monthly meetings for senior executives from a range of industries. Previous speakers have included Bill Gates, Jack Dorsey, Ana Botin, and Mark Carney.

In his spare time, John is a keen cyclist and plays chess. He also takes his long-suffering son to support Sunderland football club.

Alex Turkeltaub_Web
Alex Turkeltaub
CEO and Co-Founder, Roam Analytics

Alex is the Co-Founder and Chief Executive of Roam. Prior to Roam, Alex co-founded and was the Chief Executive of Frontier Strategy Group (FSG), a venture-backed data and analytics company focused on emerging markets, which currently serves over 250 leading multinationals. Alex and his family immigrated to the United States from the Soviet Union in 1988; he holds BA and MA degrees in International Relations from Stanford University and a JD from the Yale Law School.

2017 EDITION PROGRAM


View event schedule below.

Wednesday, May 10, 2017
6pm
Cocktails and hors d'oeuvres
Venue: Cantor Arts Center, Stanford University, Palo Alto

7pm
Keynote Conversation: Understanding the Global Context in the Age of Nationalism
Niall Ferguson, Rupert Murdoch, Martin Sorrell | Moderator: Peter Robinson
Venue: Cantor Arts Center, Stanford University, Palo Alto

Thursday, May 11, 2017
8am – 9am
Networking Breakfast
Venue: Stanford University – Palo Alto, Li Ka Shing Learning and Knowledge Center

9:00am - 9:10am
Welcoming remarks
Sir Martin Sorrell
Venue: Stanford University – Palo Alto, Li Ka Shing Learning and Knowledge Center

9:10am – 10:00am
Opening plenary: Health and Technology Convergence, Value-Driven Care, and the Role of Artificial Intelligence
George Barrett, Peter Brabeck-Letmathe, Jeff Kindler, Andy Slavitt | Moderator: Jeff George
Venue: Stanford University – Palo Alto, Li Ka Shing Learning and Knowledge Center

How real is the shift to outcomes-based or value-based health care? What will it take from key stakeholders to make the transition? Is “selling solutions rather than products” a marketing gimmick or a true change in business models? Is AI/machine learning the path to this transition or another false promise?

10:00am – 10:30am
Networking Break
Venue: Stanford University – Palo Alto, Li Ka Shing Learning and Knowledge Center

10:30am – 11:25am
Plenary: What On Earth Happens Now? The Future of Healthcare Delivery
Jay Bhattacharya, M.D., Mark McClellan, M.D., The Honorable Mick Mulvaney, Peter Orszag | Moderator: Gray Davis
Venue: Stanford University – Palo Alto, Li Ka Shing Learning and Knowledge Center

The Republican Health Care Bill narrowly emerged from the House, but its future remains murky, and likely to be drawn out. What happens now? What are plausible outcomes? And how will the industry react to the ongoing regulatory uncertainty?

11:25am – 11:45am
In Conversation: Healthcare and technology leaders in interactive discussion
Peter Brabeck-Letmathe, Ron Cohen, M.D., John Thornhill
Venue: Stanford University – Palo Alto, Li Ka Shing Learning and Knowledge Center

11:45am – 12:45pm
Lunch and Networking
Venue: Stanford University – Palo Alto, Li Ka Shing Learning and Knowledge Center

12:45pm – 1:30pm
Plenary: Real World Evidence: Hype or Reality?
Hans-Georg Eichler, M.D, John Glasspool, Gigi Hirsch, M.D., Lloyd B. Minor, M.D. | Moderator: Susan Schaeffer
Venue: Stanford University – Palo Alto, Li Ka Shing Learning and Knowledge Center

A new era of healthcare innovation could be unleashed by merging multiple sources of patient data to make treatment more personalized and effective—but the barriers are formidable. Will we ever fully realize a robust RWE system?

1:30pm – 2:20pm
Plenary: Software Eats the World – How AI and Machine Learning Are Transforming Other Industries
Paul Cheesbrough, Joe Lonsdale | Moderator: Mehran Sahami
Venue: Stanford University – Palo Alto, Li Ka Shing Learning and Knowledge Center

Artificial intelligence and machine learning are transforming other industries. What lessons can be learned from them that are relevant to leaders in health care?

2:20pm – 3:15pm
Networking Break
Venue: Stanford University – Palo Alto, Li Ka Shing Learning and Knowledge Center

3:15pm – 4:10pm
Plenary: From the Technical to the Practical – What Can AI & Machine Learning Truly Deliver in Health Care?
Shiva Kumar, Andrew Maas, Peter Ohnemus, Judy Sewards | Moderator: Chris Potts
Venue: Stanford University – Palo Alto, Li Ka Shing Learning and Knowledge Center

Innovations in machine learning and artificial intelligence are reshaping how patients are treated. What is the precise nature of these innovations? What are the associated benefits, challenges and responsibilities?

4:10pm – 5:00pm
Closing plenary: Radical Change or Gradual Evolution – What Will the Health System Be Like in Five Years?
Adam Berger, Jonathan Peacock, Robert Robbins, M.D., Alex Turkeltaub | Moderator: Jeff Kindler
Venue: Stanford University – Palo Alto, Li Ka Shing Learning and Knowledge Center

Value-based healthcare represents a paradigmatic shift for the industry. How will leaders, organizations and policymakers need to adapt? What will we be talking about a year from now? Five years from now? What will it take to be a winner in this new world?

INSIGHTS


AI Data Diluge

Remember when healthcare was hungry for data? Squeezed by pressure to reduce costs, improve outcomes, and demonstrate value, healthcare leaders demanded access to real-world data. Fast forward to the present and it seems we’ve reached the promised land where health information flows in abundance...

Read More
Artificial-intelligence-no-future-present-000081671967_XXXLarge
lighthealth| INSIGHTS

The Washington fight over the future of Obamacare will have enormous repercussions for our health care system, which now accounts for nearly 18 percent of the U.S. economy. But that impact pales before the transformation already underway due to the rise of artificial intelligence (AI) and machine learning.

Read More
2
lighthealth| INSIGHTS

Over the last several years, political clients engage in more “big data” modeling and micro-targeting than ever before in order to win their campaigns. We are beginning to see some of our corporate and institutional clients follow suit, and we anticipate that this trend will only continue and intensify.

Read More
View More

NEWS / PRESS


    • $100

    • 105 UPMC Innovates: Lessons Learned from LIGHT Forum `17

    • News — May 22, 2017

      UPMC Innovates: Lessons Learned from LIGHT Forum `17

      UPMC HealthBeat - Representatives from UPMC earlier this month attended the inaugural Leaders in Global Healthcare and Technology (LIGHT) Forum at Stanford University’s campus in Palo Alto, California...


      View
    • Register
    • $100

    • 110 In-Depth: AI in Healthcare- Where we are now and what’s next

    • News — May 19, 2017

      In-Depth: AI in Healthcare- Where we are now and what's next

      MobiHealthNews - The problem we are trying to solve is one of productivity,” said Andy Slavitt, the former acting administrator of the Centers for Medicare and Medicaid Services said during the Light Forum.


      View
    • Register
    • $100

    • 115 The Inaugural LIGHT Forum Explored the Fundamental Transformation of Healthcare through the Power of Machine Learning and Artificial Intelligence

    • Press Release — May 18, 2017

      The Inaugural LIGHT Forum Explored the Fundamental Transformation of Healthcare through the Power of Machine Learning and Artificial Intelligence

      Healthcare Facilities Today - At the heart of the Forum was the healthcare industry’s shift from selling products to offering solutions — moving towards a system founded on value and outcomes...


      View
    • Register
    • $100

    • 120 Technology is the tool to spur a healthcare revolution

    • News — May 15, 2017

      Technology is the tool to spur a healthcare revolution

      Financial Times - How AI can be further applied to the sector was the subject of the LIGHT Forum at Stanford last week.The forum’s recurring themes were that new technologies could help people take more responsibility for their own health...


      View
    • Register
    • $100

    • 125 Bloomberg Interview – Alex Turkeltaub

    • Video — May 15, 2017

      Roam Analytics CEO Alex Turkeltaub Interviewed on Bloomberg

      Bloomberg - Alex Turkeltaub co-founder and CEO of ROAM Analytics talks about the rise of AI at the LIGHT Forum in Stanford, California.


      View
    • Register
    • $100

    • 140 Bloomberg Interview – Peter Orszag

    • Video — May 12, 2017

      Peter Orszag Says ‘Math Doesn’t Work’ on GOP Health Bill

      Bloomberg - Peter Orszag, former director of the Office of Management and Budget, discusses the prospects for the GOP health bill with Bloomberg's Mike McKee


      View
    • Register
    • $100

    • 145 Bloomberg Interview – Gray Davis

    • Video — May 12, 2017

      Gray Davis on GOP Health-Care Bill, California’s Economy

      Bloomberg - Former California Governor Gray Davis discusses the GOP health-care bill and California's economy.


      View
    • Register
    • $100

    • 150 How Trump could bring drug prices down

    • News — May 12, 2017

      How Trump could bring drug prices down

      Washington Post - Mulvaney explained at the LIGHT Forum at Stanford University that drugmakers receive a “tremendous giveaway” from Medicare's prescription drug benefit.


      View
    • Register
    • $100

    • 155 A Top Trump Official Just Flunked The Jimmy Kimmel Test

    • News — May 12, 2017

      A Top Trump Official Just Flunked The Jimmy Kimmel Test

      HuffPost - Mulvaney, made the comments during the LIGHT Forum in response to a question about the “Jimmy Kimmel Test.”


      View
    • Register
    • $100

    • 160 Press Release – May 12

    • Press Release — May 12, 2017

      The Inaugural LIGHT Forum Explored the Fundamental Transformation of Healthcare through the Power of Machine Learning and Artificial Intelligence

      Over 250 global health and technology leaders attended the first-ever LIGHT Forum, focused on the transformational impact of data, artificial intelligence (AI) and machine learning (ML) on the global healthcare system....


      View
    • Register
    • $100

    • 165 Bloomberg Interview – Sir Martin Sorrell

    • Video — May 11, 2017

      WPP CEO Sees Amazon as Search Threat to Google

      Bloomberg - Martin Sorrell, CEO at WPP PLC, discusses the changes tech is bringing about in the ad industry. He speaks with Bloomberg's Michael McKee from the LIGHT Summit at Stanford University


      View
    • Register
    • $100

    • 170 Bloomberg Interview – Joe Lonsdale

    • Video — May 11, 2017

      Joe Lonsdale Sees Tech and Health Care Intersecting

      Bloomberg - Joe Lonsdale, 8VC founding partner, discusses tech's impact on healthcare with Bloomberg's Mike McKee


      View
    • Register
    • $100

    • 175 Mulvaney Agrees With ‘Jimmy Kimmel Test’

    • News — May 11, 2017

      Mulvaney Agrees With ‘Jimmy Kimmel Test’

      Washington Examiner - Mulvaney was asked by a member of the audience at the Light Forum at Stanford University in Palo Alto, Calif., if he agreed.


      View
    • Register
    • $100

    • 180 Trump and Obama budget chiefs spar over Obamacare replacement

    • News — May 11, 2017

      Trump and Obama budget chiefs spar over Obamacare replacement

      Washington Examiner - Mulvaney, President Trump's budget chief, and Orszag, who held the role for a time under former President Barack Obama, sparred Thursday at the Light Forum.


      View
    • Register
    • $100

    • 185 WPP’s Sorrell: Amazon Search Threat To Google

    • News — May 11, 2017

      WPP's Sorrell: Amazon Search Threat To Google

      Mediapost - At the LIGHT Summit, Sorrell said the group discussed the rise of Amazon because the company "is certainly a threat to Google in search."


      View
    • Register
    • Press Release

    • 190 Press Release – May 04

    • Press Release — May 04, 2017

      LIGHT Forum Reveals Final Speaker Lineup

      The upcoming LIGHT Forum 2017 on 10-11 May, will convene more than 200 high-level executives, medical technologists, and policymakers in global health and technology, to explore the impact and implications of AI and machine learning on health outcomes and business models...


      View
    • Register
    • Press Release

    • 195 Press Release – Mar 30

    • Press Release — Mar 30, 2017

      Leaders to Explore How AI is Transforming Healthcare Industry at First-ever LIGHT Forum at Stanford University on May 10-11

      With the future of healthcare dominating the news, more than 200 high-level executives and policymakers will explore how AI and machine learning innovations are transforming the industry...


      View
    • Register
    • Press Release

    • 200 Press Release – Feb 2, 2017

    • Press Release — Feb 2, 2017

      Forum Shedding Light on Artificial Intelligence Disruptions in Healthcare

      Bringing together leaders from a cross-section of Silicon Valley AI innovators, healthcare executives and top policy makers, LIGHT Forum explores how AI is shaping the healthcare industry...


      View
    • Register

CONTACT


Contact for LIGHT Forum 2018

+1 212 794 8801
contact@light2018.com